scispace - formally typeset
R

Ron Pisters

Researcher at Maastricht University Medical Centre

Publications -  83
Citations -  12119

Ron Pisters is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 24, co-authored 67 publications receiving 10515 citations. Previous affiliations of Ron Pisters include Maastricht University & University of Birmingham.

Papers
More filters
Journal ArticleDOI

Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial.

TL;DR: Dronedarone on top of standard care in AF patients with CHD reduced cardiovascular hospitalization or death similar to that in the overall ATHENA population, and reduced a first acute coronary syndrome.
Journal ArticleDOI

Clinical and echocardiographic correlates of intra-atrial conduction delay

TL;DR: It is found that the PA-TDI was independently prolonged in patients with a history of AF, hypertension, valve disease, higher age, and a higher BMI, suggesting that early and aggressive treatment of hypertension, diastolic dysfunction, and obesity could prevent intra-atrial conduction delay.
Journal ArticleDOI

The occurrence of cardiovascular disease during 5-year follow-up in patients with idiopathic atrial fibrillation

TL;DR: Patients originally diagnosed with idiopathic AF develop CVD more often, at younger age, and with a more severe disease profile compared with healthy sinus rhythm control patients, suggesting the detection and treatment of CVD in an early stage could improve the prognosis of these patients.
Journal ArticleDOI

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry

TL;DR: In the Dutch subset of the XANTUS registry, low rates of major bleeding and label-discordant dosing and high persistence rates during one year of follow-up in patients receiving rivaroxaban in routine clinical practice are observed.